Quoin Pharmaceuticals Signs Exclusive Distribution Agreement with Orpharm LLC for its Lead Asset, QRX003, for Netherton Syndrome
December 15, 2021 09:00 ET
|
Quoin Pharmaceuticals, Inc.
ASHBURN, Va., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today...
Quoin Pharmaceuticals and Genpharm Services Sign Exclusive License and Distribution Agreement for Quoin’s Lead Asset, QRX003
November 11, 2021 08:30 ET
|
Quoin Pharmaceuticals, Inc.
ASHBURN, Va., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, and...
Quoin Pharmaceuticals Signs Exclusive Licensing and Distribution Agreement with AFT Pharmaceuticals for its Lead Asset, QRX003
November 08, 2021 08:00 ET
|
Quoin Pharmaceuticals, Inc.
AFT Gains Exclusive Rights to Commercialize QRX003 in Australia and New Zealand ASHBURN, Va., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”),...
Quoin Pharmaceuticals Appoints Gordon Dunn as Chief Financial Officer
November 04, 2021 09:25 ET
|
Quoin Pharmaceuticals, Inc.
ASHBURN, Va., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today...
Quoin Pharmaceuticals Announces Signing of Exclusive License from Queensland University of Technology, Australia
November 02, 2021 08:30 ET
|
Quoin Pharmaceuticals, Inc.
ASHBURN, Va., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today...